---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-010575"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:50:45.368436+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports FY2024 net loss $37.6M; initiates Phase 3 Versamune HPV trial

## Summary
- Net loss for FY 2024 was $37.6M ($1.03 per share), compared to $42.9M ($1.39 per share) in 2023; operating expenses decreased to $36.3M from $43.0M.
- Initiated Phase 3 VERSATILE-003 trial for Versamune HPV in HPV16-positive first-line recurrent/metastatic HNSCC; ~350 patients, primary endpoint overall survival.
- FDA cleared IND for combination of Versamune MUC1 and PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma; Phase 1/2 with NCI.
- Cash balance as of Dec 31, 2024 was $41.7M; subsequent $22M registered direct offering in Feb 2025 with $11M upfront proceeds.
- FDA granted Fast Track designation for Versamune HPV + pembrolizumab combination in recurrent/metastatic HNSCC.

## SEC filing metadata
- accession: 0001140361-25-010575
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125010575/0001140361-25-010575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125010575/ef20046266_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-010575
- JSON: https://secwatch.observer/filing/0001140361-25-010575.json
- Plain text: https://secwatch.observer/filing/0001140361-25-010575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.